

Genevieve M Boland

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5995249/publications.pdf>

Version: 2024-02-01

108
papers

10,534
citations

76294

40
h-index

40954

93
g-index

116
all docs

116
docs citations

116
times ranked

17153
citing authors

#	ARTICLE	IF	CITATIONS
1	Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. <i>Cell</i> , 2018, 175, 998-1013.e20.	13.5	1,260
2	A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. <i>Cell</i> , 2018, 175, 984-997.e24.	13.5	892
3	Resistance to checkpoint blockade therapy through inactivation of antigen presentation. <i>Nature Communications</i> , 2017, 8, 1136.	5.8	686
4	Toward Minimal Residual Disease-Directed Therapy in Melanoma. <i>Cell</i> , 2018, 174, 843-855.e19.	13.5	514
5	CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. <i>Cancer Discovery</i> , 2018, 8, 216-233.	7.7	503
6	Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. <i>Nature Medicine</i> , 2018, 24, 1545-1549.	15.2	473
7	Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy. <i>Immunity</i> , 2019, 50, 1498-1512.e5.	6.6	406
8	<i>Ex Vivo</i> Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. <i>Cancer Discovery</i> , 2018, 8, 196-215.	7.7	392
9	Lineage Tracing in Humans Enabled by Mitochondrial Mutations and Single-Cell Genomics. <i>Cell</i> , 2019, 176, 1325-1339.e22.	13.5	345
10	The Human and Mouse Enteric Nervous System at Single-Cell Resolution. <i>Cell</i> , 2020, 182, 1606-1622.e23.	13.5	287
11	Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy. <i>Cell</i> , 2020, 182, 655-671.e22.	13.5	259
12	Spatially organized multicellular immune hubs in human colorectal cancer. <i>Cell</i> , 2021, 184, 4734-4752.e20.	13.5	256
13	Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma. <i>Nature</i> , 2021, 596, 119-125.	13.7	239
14	Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response. <i>Cancer Research</i> , 2017, 77, 2318-2327.	0.4	235
15	PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance. <i>Nature Immunology</i> , 2019, 20, 1231-1243.	7.0	217
16	Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. <i>Nature Medicine</i> , 2020, 26, 1114-1124.	15.2	216
17	Association between adherence to National Comprehensive Cancer Network treatment guidelines and improved survival in patients with colon cancer. <i>Cancer</i> , 2013, 119, 1593-1601.	2.0	182
18	Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5586-5594.	3.2	178

#	ARTICLE	IF	CITATIONS
19	NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 364-376.	2.3	167
20	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncology, The, 2019, 20, e378-e389.	5.1	155
21	Massively parallel single-cell mitochondrial DNA genotyping and chromatin profiling. Nature Biotechnology, 2021, 39, 451-461.	9.4	150
22	PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature, 2017, 550, 133-136.	13.7	146
23	Beyond BRAF V600 : Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma. Journal of Investigative Dermatology, 2015, 135, 508-515.	0.3	138
24	Differential pre-malignant programs and microenvironment chart distinct paths to malignancy in human colorectal polyps. Cell, 2021, 184, 6262-6280.e26.	13.5	125
25	The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis. Cancer Discovery, 2021, 11, 678-695.	7.7	114
26	Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma. Journal of Clinical Investigation, 2015, 125, 1459-1470.	3.9	106
27	The Effectiveness of Checkpoint Inhibitor Combinations and Administration Timing Can Be Measured by Granzyme B PET Imaging. Clinical Cancer Research, 2019, 25, 1196-1205.	3.2	85
28	Co-targeting <i>BET</i> and <i>MEK</i> as salvage therapy for <i>MAPK</i> and checkpoint inhibitor-resistant melanoma. EMBO Molecular Medicine, 2018, 10, .	3.3	79
29	Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence. Cell Reports, 2017, 21, 2796-2812.	2.9	77
30	A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of <i>BRAF</i> -mutated Melanoma to MAPK Inhibitors. Clinical Cancer Research, 2019, 25, 6852-6867.	3.2	74
31	ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma. Cancer Discovery, 2019, 9, 396-415.	7.7	71
32	Reversal of pre-existing NGFR-driven tumor and immune therapy resistance. Nature Communications, 2020, 11, 3946.	5.8	71
33	Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy. Clinical Cancer Research, 2021, 27, 5993-6000.	3.2	70
34	Landscape of helper and regulatory antitumour CD4+ T cells in melanoma. Nature, 2022, 605, 532-538.	13.7	70
35	Evolution of delayed resistance to immunotherapy in a melanoma responder. Nature Medicine, 2021, 27, 985-992.	15.2	67
36	Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells. Oncotarget, 2017, 8, 25395-25417.	0.8	64

#	ARTICLE	IF	CITATIONS
37	A Serum Protein Signature Associated with Outcome after Anti-PD-1 Therapy in Metastatic Melanoma. <i>Cancer Immunology Research</i> , 2018, 6, 79-86.	1.6	61
38	Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	54
39	Clinical next generation sequencing to identify actionable aberrations in a phase I program. <i>Oncotarget</i> , 2015, 6, 20099-20110.	0.8	41
40	Clinical Observations and Molecular Variables of Primary Vascular Leiomyosarcoma. <i>JAMA Surgery</i> , 2016, 151, 347.	2.2	40
41	Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 897-905.	2.0	38
42	Plasma-derived extracellular vesicle analysis and deconvolution enable prediction and tracking of melanoma checkpoint blockade outcome. <i>Science Advances</i> , 2020, 6, .	4.7	37
43	The Role of Surgery for Melanoma in an Era of Effective Systemic Therapy. <i>Current Oncology Reports</i> , 2017, 19, 17.	1.8	30
44	Principles of Melanoma Staging. <i>Cancer Treatment and Research</i> , 2016, 167, 131-148.	0.2	29
45	Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. <i>Clinical Cancer Research</i> , 2018, 24, 4771-4784.	3.2	29
46	Sentinel Lymph Node Biopsy in Melanoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2012, 18, 185-191.	1.0	28
47	Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy. <i>Molecular Systems Biology</i> , 2019, 15, e8323.	3.2	25
48	Rapid corticosteroid taper versus standard of care for immune checkpoint inhibitor induced nephritis: a single-center retrospective cohort study. , 2021, 9, e002292.		25
49	Absolute quantification of tumor antigens using embedded MHC-I isotopologue calibrants. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	25
50	Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma. <i>Clinical Cancer Research</i> , 2020, 26, 6039-6050.	3.2	24
51	Mixed Response to Immunotherapy in Patients with Metastatic Melanoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 3488-3497.	0.7	24
52	Targeting the cyclin-dependent kinase 5 in metastatic melanoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 8001-8012.	3.3	21
53	Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma. <i>Nature Communications</i> , 2021, 12, 6023.	5.8	21
54	Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). <i>Annals of Surgical Oncology</i> , 2022, 29, 3694-3708.	0.7	21

#	ARTICLE	IF	CITATIONS
55	Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study. <i>British Journal of Dermatology</i> , 2022, 187, 401-410.	1.4	21
56	STAG2 regulates interferon signaling in melanoma via enhancer loop reprogramming. <i>Nature Communications</i> , 2022, 13, 1859.	5.8	21
57	Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition. <i>Cancer Immunology Research</i> , 2022, 10, 996-1012.	1.6	18
58	Metastatic melanoma with spontaneous complete regression of a thick primary lesion. <i>JAAD Case Reports</i> , 2016, 2, 439-441.	0.4	16
59	Melanoma: Advances in Targeted Therapy and Molecular Markers. <i>Annals of Surgical Oncology</i> , 2015, 22, 3451-3458.	0.7	15
60	Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee. , 2020, 8, e001583.		15
61	CRISPR Screens Identify Essential Cell Growth Mediators in BRAF Inhibitor-resistant Melanoma. <i>Genomics, Proteomics and Bioinformatics</i> , 2020, 18, 26-40.	3.0	14
62	Use of immunotherapy and surgery for stage IV melanoma. <i>Cancer</i> , 2020, 126, 2614-2624.	2.0	14
63	Type 2 immunity is maintained during cancer-associated adipose tissue wasting. <i>Immunotherapy Advances</i> , 2021, 1, ltab011.	1.2	13
64	Adjuvant Therapy Failure Patterns in the Modern Era of Melanoma Management. <i>Annals of Surgical Oncology</i> , 2020, 27, 5128-5136.	0.7	13
65	Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma. <i>Cell Reports Medicine</i> , 2022, 3, 100500.	3.3	13
66	Low expression of the PPAR γ -regulated gene thioredoxin-interacting protein accompanies human melanoma progression and promotes experimental lung metastases. <i>Scientific Reports</i> , 2021, 11, 7847.	1.6	12
67	A plasma-only integrated genomic and epigenomic circulating tumor DNA (ctDNA) assay to inform recurrence risk in colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 3602-3602.	0.8	12
68	Atypical ALK α -positive Spitz tumors with 9p21 homozygous deletion: Report of two cases and review of the literature. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 136-140.	0.7	11
69	Successful Mentor-Mentee Relationship. <i>Journal of Surgical Research</i> , 2020, 247, 332-334.	0.8	11
70	Integration of Digital Pathologic and Transcriptomic Analyses Connects Tumor-Infiltrating Lymphocyte Spatial Density With Clinical Response to BRAF Inhibitors. <i>Frontiers in Oncology</i> , 2020, 10, 757.	1.3	11
71	Temporal Trends in Inpatient Oncology Census Before and During the COVID-19 Pandemic and Rates of Nosocomial COVID-19 Among Patients with Cancer at a Large Academic Center. <i>Oncologist</i> , 2021, 26, e1427-e1433.	1.9	11
72	NCCN Guidelines Insights: Uveal Melanoma, Version 1.2019. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 120-131.	2.3	11

#	ARTICLE	IF	CITATIONS
73	Tracking early response to immunotherapy. <i>Nature Cancer</i> , 2020, 1, 160-162.	5.7	9
74	Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance. <i>Cancer Research</i> , 2021, 81, 5230-5241.	0.4	9
75	Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer. , 2021, 9, e002886.		9
76	Oncolytic Immunotherapy. <i>Surgical Oncology Clinics of North America</i> , 2019, 28, 419-430.	0.6	8
77	Adjuvant Radiation Therapy for Clinical Stage III Melanoma in the Modern Therapeutic Era. <i>Annals of Surgical Oncology</i> , 2021, 28, 3512-3521.	0.7	8
78	Surgical delay and mortality for primary cutaneous melanoma. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1089-1091.	0.6	8
79	Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort. , 2021, 9, e002092.		7
80	Immune checkpoint inhibition (ICI) in advanced cutaneous squamous cell carcinoma (cSCC): Clinical response and correlative biomarker analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9564-9564.	0.8	7
81	PIVOT-12: a phase III study of adjuvant bempedalesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence. <i>Future Oncology</i> , 2022, 18, 903-913.	1.1	7
82	The role of surgeons in building a personalized medicine program. <i>Journal of Surgical Oncology</i> , 2015, 111, 3-8.	0.8	5
83	Association between serum lactate dehydrogenase and cutaneous immune-related adverse events among patients on immune checkpoint inhibitors for advanced melanoma. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 1147-1149.	0.6	4
84	Glycoproteomics as a powerful liquid biopsy-based predictor of checkpoint inhibitor treatment benefit in metastatic malignant melanoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9545-9545.	0.8	4
85	Impact of Cancer History on Outcomes Among Hospitalized Patients with COVID-19. <i>Oncologist</i> , 2021, 26, 685-693.	1.9	3
86	Abstract 2030: A single-cell spatially resolved map of colorectal cancer identifies novel spatial relationships between cancer cells and the microenvironment. <i>Cancer Research</i> , 2022, 82, 2030-2030.	0.4	3
87	Incorporating Well-Being into Mentorship Meetings: A Case Demonstration at Massachusetts General Hospital Department of Surgery a Harvard Medical School Affiliate. <i>American Journal of Lifestyle Medicine</i> , 2023, 17, 213-215.	0.8	3
88	The Patient Speaks: Importance of Patient Perspectives in Clinical Decision-Making. <i>Annals of Surgical Oncology</i> , 2019, 26, 2665-2666.	0.7	2
89	Predictable early onset high-dose-glucocorticoid-associated irAE and its predictive role in anti-PD-1 monotherapy treated advanced melanoma patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9544-9544.	0.8	2
90	920â€¦A single-cell spatially resolved MERFISH map of the colorectal tumor immune microenvironment. , 2021, 9, A965-A965.		2

#	ARTICLE	IF	CITATIONS
91	Lymphatic versus Hematogenous Melanoma Metastases: Support for Biological Heterogeneity without Clear Clinical Application. <i>Journal of Investigative Dermatology</i> , 2017, 137, 2466-2468.	0.3	1
92	Characterizing the tumor and immune landscape of melanoma patients treated with combined checkpoint blockade and MAPK targeted therapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9522-9522.	0.8	1
93	Discrepancies in response and immune-related adverse events (irAE) of anti-PD-1 monotherapy between races and primary sites in patients (pts) with advanced nonacral cutaneous melanoma (NACM).. <i>Journal of Clinical Oncology</i> , 2021, 39, 9530-9530.	0.8	1
94	Liquid biopsy using plasma proteomic profiling to reveal predictors of immunotherapy response.. <i>Journal of Clinical Oncology</i> , 2019, 37, 130-130.	0.8	1
95	Harnessing the Potential of Combination Immunotherapy and Oncolytic Virotherapy for Solid Tumors. <i>Annals of Surgical Oncology</i> , 2022, 29, 762-763.	0.7	1
96	Spatial transcriptomics characterization of hepatocellular carcinoma using Molecular Cartography.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16110-e16110.	0.8	1
97	Single-cell profiling of human heart and blood in immune checkpoint inhibitor-associated myocarditis.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2507-2507.	0.8	1
98	ASO Author Reflections: Mixed Response in Metastatic Melanoma Patients Treated with Immunotherapy. <i>Annals of Surgical Oncology</i> , 2020, 27, 3498-3499.	0.7	0
99	ASO Author Reflections: Adjuvant Treatment of Melanoma in the Modern Era. <i>Annals of Surgical Oncology</i> , 2020, 27, 5137-5138.	0.7	0
100	Prognostic models for advanced melanoma patients treated with anti-PD-1 monotherapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, 133-133.	0.8	0
101	Use of immunotherapy for stage-III and IV melanoma and likelihood of regional and distant lymph node resection and surgical resection for distant metastasis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9558-9558.	0.8	0
102	Organ site-specific radiological responses in anti-PD-1 monotherapy treated advanced melanoma patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9552-9552.	0.8	0
103	Investigating the tumor immune infiltrate for populations that predict immune-related adverse events (irAEs) in patients receiving PD-1 inhibitors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3116-3116.	0.8	0
104	The use of plasma proteomic markers to understand the biology of immunotherapy response.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10062-10062.	0.8	0
105	641â€¦Spatially organized multicellular immune hubs in MMRd and MMRp colorectal cancer. , 2021, 9, A670-A670.		0
106	MO344: Effect of Cancer Stage on Adverse Kidney Outcomes in Patients With Advanced Melanoma Treated With Immune Checkpoint Inhibitors. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.4	0
107	Abstract 1270: Glycoproteomics-based liquid biopsy informs optimal checkpoint-inhibitor drug choice. <i>Cancer Research</i> , 2022, 82, 1270-1270.	0.4	0
108	Abstract 3610: In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer. <i>Cancer Research</i> , 2022, 82, 3610-3610.	0.4	0